metformin has been researched along with HIV Coinfection in 50 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conducted a Phase II double-blind placebo-controlled trial that aimed to determine the impact of metformin on blood glucose levels among people with prediabetes (defined as impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) and HIV in SSA." | 9.69 | Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial. ( Alam, U; Bates, K; Charles, G; Garrib, A; Jaffar, S; Kivuyo, S; Luo, H; Majaliwa, E; Mfinanga, S; Nyirenda, MJ; Ramaiya, K; Simbauranga, R; van Widenfelt, E; Wang, D, 2023) |
| "Fifty HIV-infected subjects with the metabolic syndrome were previously recruited and randomized to receive lifestyle modification (LSM) and/or metformin over 12 months." | 9.20 | Effects of lifestyle modification and metformin on irisin and FGF21 among HIV-infected subjects with the metabolic syndrome. ( Cypess, AM; Fitch, KV; Grinspoon, SK; Petrow, E; Srinivasa, S; Torriani, M; Wei, J; Wong, K, 2015) |
| " We hypothesized that lifestyle modification (LSM) and metformin would improve CVD indices in HIV patients with metabolic syndrome." | 9.16 | Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. ( Abbara, S; Fitch, K; Grinspoon, S; Hemphill, L; Lee, H; Michel, T; Sacks, R; Stavrou, E; Torriani, M, 2012) |
| "To evaluate and compare effects of 48-week treatment with rosiglitazone and metformin on insulin resistance in patients infected with Human Immunodeficiency Virus (HIV) receiving highly active antiretroviral therapy (HAART), containing a protease inhibitor." | 9.12 | Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial. ( Janez, A; Karner, P; Maticic, M; Sharma, P; Silic, A; Tomazic, J; Vidmar, L, 2007) |
| "To compare the effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone and metformin for treating HIV lipodystrophy." | 9.11 | Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. ( Cabezas, MC; de Koning, EJ; Hoepelman, AI; Joven, J; op't Roodt, J; Rabelink, TJ; van Wijk, JP, 2005) |
| "This study suggests that a relatively low dosage of metformin reduces insulin resistance and related cardiovascular risk parameters in HIV-infected patients with lipodystrophy." | 9.09 | Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. ( Basgoz, N; Corcoran, C; Davis, B; Grinspoon, S; Hadigan, C; Sax, P, 2000) |
| "We present an uncommon case of lactic acidosis after concomitant administration of Metformin and Tenofovir." | 7.77 | Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection. ( Alivanis, P; Aperis, G; Arvanitis, A; Paliouras, C; Zervos, A, 2011) |
| " During the first year of treatment, exenatide, in combination with metformin and repaglinide, led to a weight loss of 14 kg and fat mass and waist circumference were respectively reduced from 31 to 25." | 7.77 | Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. ( Buysschaert, M; de la Tribonnière, X; Hermans, MP; Oriot, P; Selvais, P, 2011) |
| "Secondary outcomes include changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures, changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters." | 6.82 | Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016) |
| "Metformin was well tolerated and no one discontinued treatment due to side effects." | 6.70 | Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. ( Grinspoon, S; Hadigan, C; Rabe, J, 2002) |
| " We conducted a Phase II double-blind placebo-controlled trial that aimed to determine the impact of metformin on blood glucose levels among people with prediabetes (defined as impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) and HIV in SSA." | 5.69 | Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial. ( Alam, U; Bates, K; Charles, G; Garrib, A; Jaffar, S; Kivuyo, S; Luo, H; Majaliwa, E; Mfinanga, S; Nyirenda, MJ; Ramaiya, K; Simbauranga, R; van Widenfelt, E; Wang, D, 2023) |
| "Fifty HIV-infected subjects with the metabolic syndrome were previously recruited and randomized to receive lifestyle modification (LSM) and/or metformin over 12 months." | 5.20 | Effects of lifestyle modification and metformin on irisin and FGF21 among HIV-infected subjects with the metabolic syndrome. ( Cypess, AM; Fitch, KV; Grinspoon, SK; Petrow, E; Srinivasa, S; Torriani, M; Wei, J; Wong, K, 2015) |
| " We hypothesized that lifestyle modification (LSM) and metformin would improve CVD indices in HIV patients with metabolic syndrome." | 5.16 | Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. ( Abbara, S; Fitch, K; Grinspoon, S; Hemphill, L; Lee, H; Michel, T; Sacks, R; Stavrou, E; Torriani, M, 2012) |
| "We conducted a randomized placebo-controlled trial to examine the effects of metformin on visceral adipose tissue (VAT), appendicular fat, lipid profile and insulin sensitivity in HIV-infected persons with central adiposity and mild insulin resistance." | 5.12 | A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. ( Gorbach, S; Kohli, R; Shevitz, A; Wanke, C, 2007) |
| "To evaluate and compare effects of 48-week treatment with rosiglitazone and metformin on insulin resistance in patients infected with Human Immunodeficiency Virus (HIV) receiving highly active antiretroviral therapy (HAART), containing a protease inhibitor." | 5.12 | Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial. ( Janez, A; Karner, P; Maticic, M; Sharma, P; Silic, A; Tomazic, J; Vidmar, L, 2007) |
| "To compare the effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone and metformin for treating HIV lipodystrophy." | 5.11 | Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. ( Cabezas, MC; de Koning, EJ; Hoepelman, AI; Joven, J; op't Roodt, J; Rabelink, TJ; van Wijk, JP, 2005) |
| "This study suggests that a relatively low dosage of metformin reduces insulin resistance and related cardiovascular risk parameters in HIV-infected patients with lipodystrophy." | 5.09 | Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. ( Basgoz, N; Corcoran, C; Davis, B; Grinspoon, S; Hadigan, C; Sax, P, 2000) |
| " We also followed up a subset of male patients with HIV and hepatitis C virus (HCV) coinfection (n = 47) who were not receiving antiviral treatment and for whom metformin was prescribed for insulin resistance, which tends to have a higher incidence and severity in coinfected patients." | 3.79 | Metformin: a cheap and well-tolerated drug that provides benefits for viral infections. ( Alonso-Villaverde, C; Aragonès, G; Beltrán-Debón, R; Camps, J; Espinel, E; Fernandez-Sender, L; Joven, J; Menéndez, JA; Pedro-Botet, J; Riera-Borrull, M; Rodríguez-Gallego, E; Rull, A, 2013) |
| "We present an uncommon case of lactic acidosis after concomitant administration of Metformin and Tenofovir." | 3.77 | Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection. ( Alivanis, P; Aperis, G; Arvanitis, A; Paliouras, C; Zervos, A, 2011) |
| " During the first year of treatment, exenatide, in combination with metformin and repaglinide, led to a weight loss of 14 kg and fat mass and waist circumference were respectively reduced from 31 to 25." | 3.77 | Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. ( Buysschaert, M; de la Tribonnière, X; Hermans, MP; Oriot, P; Selvais, P, 2011) |
| "Metformin has shown favorable clinical outcomes in enhancing the efficacy of programmed cell death-1 (PD-1) blockade and restoring antitumor T cell immunity." | 3.01 | Effects of Brief Adjunctive Metformin Therapy in Virologically Suppressed HIV-Infected Adults on Polyfunctional HIV-Specific CD8 T Cell Responses to PD-L1 Blockade. ( Alejandria, MM; Chew, GM; Chow, DC; Clements, DM; Corley, MJ; Gerschenson, M; Ndhlovu, LC; Padua, AJP; Pang, APS; Shikuma, CM; Souza, SA, 2021) |
| "Secondary outcomes include changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures, changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters." | 2.82 | Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016) |
| "Rosiglitazone may increase subcutaneous fat in some individuals." | 2.73 | Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. ( Alston-Smith, BL; Basar, MT; Fielding, RA; Grinspoon, S; Koletar, SL; Mulligan, K; Parker, RA; Schouten, JT; Wininger, DA; Yang, Y, 2007) |
| "Treatment with metformin had no significant effect on total, HDL and LDL cholesterol." | 2.71 | Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. ( Janez, A; Karner, P; Maticic, M; Sharma, PM; Tomazic, J; Vidmar, L, 2005) |
| "Metformin was well tolerated and no one discontinued treatment due to side effects." | 2.70 | Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. ( Grinspoon, S; Hadigan, C; Rabe, J, 2002) |
| "Metformin, a biguanide, has been available in the US for the treatment of type 2 diabetes mellitus for nearly 8 years." | 2.42 | Metformin: new understandings, new uses. ( Hundal, RS; Inzucchi, SE, 2003) |
| "Metformin use has been associated with beneficial effects on cognitive and physical function among older adults without HIV." | 1.91 | Association Between Metformin Use and Cognitive and Physical Function in Persons with HIV and Diabetes. ( Brown, TT; Erlandson, KM; Granche, J; Koletar, SL; Letendre, S; Masters, MC; Overton, ET; Palella, F; Rubin, LH; Tassiopoulos, K; Yang, J, 2023) |
| "Adverse drug reactions were assessed using patient-reported gastrointestinal intolerance and hypoglycemic symptoms." | 1.46 | Evaluation of the concurrent use of dolutegravir and metformin in human immunodeficiency virus-infected patients. ( Badowski, ME; Fulco, PP; Liedtke, MD; Masich, A, 2017) |
| "Type 2 diabetes is increasingly common in HIV-infected individuals." | 1.46 | Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans. ( Bisson, GP; Gibert, CL; Gordon, K; Han, JH; Leaf, DA; Rimland, D; Rodriguez-Barradas, MC; Womack, JA, 2017) |
| "Metformin use was associated with improved CD4 recovery (p=0." | 1.40 | Cohort study of diabetes in HIV-infected adult patients: evaluating the effect of diabetes mellitus on immune reconstitution. ( Cary, MS; Chikuse, F; Kwadiba, G; Moyo, D; Mushisha, O; Reid, MJ; Steenhoff, AP; Tanthuma, G, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.00) | 18.2507 |
| 2000's | 21 (42.00) | 29.6817 |
| 2010's | 18 (36.00) | 24.3611 |
| 2020's | 9 (18.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dardano, A | 1 |
| Aragona, M | 1 |
| Daniele, G | 1 |
| Miccoli, R | 1 |
| Del Prato, S | 1 |
| Masters, MC | 1 |
| Granche, J | 1 |
| Yang, J | 1 |
| Overton, ET | 1 |
| Letendre, S | 1 |
| Koletar, SL | 2 |
| Rubin, LH | 1 |
| Brown, TT | 1 |
| Tassiopoulos, K | 1 |
| Erlandson, KM | 1 |
| Palella, F | 1 |
| Zaongo, SD | 1 |
| Chen, Y | 3 |
| Garrib, A | 1 |
| Kivuyo, S | 1 |
| Bates, K | 1 |
| Ramaiya, K | 1 |
| Wang, D | 1 |
| Majaliwa, E | 1 |
| Simbauranga, R | 1 |
| Charles, G | 1 |
| van Widenfelt, E | 1 |
| Luo, H | 1 |
| Alam, U | 1 |
| Nyirenda, MJ | 1 |
| Jaffar, S | 1 |
| Mfinanga, S | 1 |
| Chen, X | 2 |
| Chen, H | 1 |
| Zhang, Z | 1 |
| Fu, Y | 1 |
| Han, X | 1 |
| Zhang, Y | 1 |
| Xu, J | 1 |
| Ding, H | 1 |
| Cui, H | 1 |
| Dong, T | 1 |
| Shang, H | 1 |
| Jiang, Y | 1 |
| Youn, B | 1 |
| Shireman, TI | 1 |
| Lee, Y | 1 |
| Galárraga, O | 1 |
| Wilson, IB | 1 |
| Ouyang, J | 2 |
| Isnard, S | 3 |
| Lin, J | 2 |
| Fombuena, B | 2 |
| Marette, A | 2 |
| Routy, B | 2 |
| Routy, JP | 3 |
| Peng, X | 1 |
| Messaoudene, M | 1 |
| Chew, GM | 1 |
| Padua, AJP | 1 |
| Chow, DC | 1 |
| Souza, SA | 1 |
| Clements, DM | 1 |
| Corley, MJ | 1 |
| Pang, APS | 1 |
| Alejandria, MM | 1 |
| Gerschenson, M | 1 |
| Shikuma, CM | 1 |
| Ndhlovu, LC | 1 |
| Cattaneo, D | 3 |
| Formenti, T | 1 |
| Minisci, D | 2 |
| Casalini, G | 1 |
| Meraviglia, P | 1 |
| Gervasoni, C | 3 |
| Guo, H | 1 |
| Wang, Q | 1 |
| Ghneim, K | 1 |
| Wang, L | 1 |
| Rampanelli, E | 1 |
| Holley-Guthrie, E | 1 |
| Cheng, L | 1 |
| Garrido, C | 1 |
| Margolis, DM | 1 |
| Eller, LA | 1 |
| Robb, ML | 1 |
| Sekaly, RP | 1 |
| Su, L | 1 |
| Ting, JP | 1 |
| Masich, A | 1 |
| Badowski, ME | 1 |
| Liedtke, MD | 1 |
| Fulco, PP | 1 |
| Naccarato, M | 1 |
| Yoong, D | 1 |
| Fong, IW | 1 |
| Resnati, C | 1 |
| Rizzardini, G | 2 |
| Mehraj, V | 1 |
| Ostrowski, M | 1 |
| Chomont, N | 1 |
| Ancuta, P | 1 |
| Ponte, R | 1 |
| Planas, D | 1 |
| Dupuy, FP | 1 |
| Angel, JB | 1 |
| Alonso-Villaverde, C | 3 |
| Menéndez, JA | 2 |
| Joven, J | 4 |
| Moyo, D | 1 |
| Tanthuma, G | 1 |
| Cary, MS | 1 |
| Mushisha, O | 1 |
| Kwadiba, G | 1 |
| Chikuse, F | 1 |
| Steenhoff, AP | 1 |
| Reid, MJ | 1 |
| Srinivasa, S | 1 |
| Wong, K | 1 |
| Fitch, KV | 1 |
| Wei, J | 1 |
| Petrow, E | 1 |
| Cypess, AM | 1 |
| Torriani, M | 3 |
| Grinspoon, SK | 1 |
| McGinty, EE | 1 |
| Baller, J | 1 |
| Azrin, ST | 1 |
| Juliano-Bult, D | 1 |
| Daumit, GL | 1 |
| Doyle, MA | 1 |
| Singer, J | 1 |
| Lee, T | 1 |
| Muir, M | 1 |
| Cooper, C | 1 |
| Han, JH | 1 |
| Gordon, K | 1 |
| Womack, JA | 1 |
| Gibert, CL | 1 |
| Leaf, DA | 1 |
| Rimland, D | 1 |
| Rodriguez-Barradas, MC | 1 |
| Bisson, GP | 1 |
| Clementi, E | 1 |
| Aperis, G | 1 |
| Paliouras, C | 1 |
| Zervos, A | 1 |
| Arvanitis, A | 1 |
| Alivanis, P | 1 |
| Oriot, P | 1 |
| Hermans, MP | 1 |
| Selvais, P | 1 |
| Buysschaert, M | 1 |
| de la Tribonnière, X | 1 |
| Kazazis, C | 1 |
| Fitch, K | 1 |
| Abbara, S | 1 |
| Lee, H | 1 |
| Stavrou, E | 1 |
| Sacks, R | 1 |
| Michel, T | 1 |
| Hemphill, L | 1 |
| Grinspoon, S | 5 |
| Fernandez-Sender, L | 1 |
| Espinel, E | 1 |
| Rull, A | 1 |
| Beltrán-Debón, R | 1 |
| Rodríguez-Gallego, E | 1 |
| Riera-Borrull, M | 1 |
| Pedro-Botet, J | 1 |
| Camps, J | 2 |
| Aragonès, G | 1 |
| Ghazourian, N | 1 |
| Hadigan, C | 4 |
| Rabe, J | 2 |
| Sattler, F | 1 |
| Hundal, RS | 1 |
| Inzucchi, SE | 1 |
| Martínez, E | 1 |
| Domingo, P | 1 |
| Ribera, E | 1 |
| Milinkovic, A | 1 |
| Arroyo, JA | 1 |
| Conget, I | 1 |
| Pérez-Cuevas, JB | 1 |
| Casamitjana, R | 1 |
| de Lazzari, E | 1 |
| Bianchi, L | 1 |
| Montserrat, E | 1 |
| Roca, M | 1 |
| Burgos, R | 1 |
| Arnaiz, JA | 1 |
| Gatell, JM | 1 |
| Driscoll, SD | 1 |
| Meininger, GE | 1 |
| Ljungquist, K | 1 |
| Klibanski, A | 1 |
| Frontera, WR | 1 |
| Martin, A | 1 |
| Mallon, PW | 1 |
| van Wijk, JP | 2 |
| de Koning, EJ | 2 |
| Cabezas, MC | 1 |
| op't Roodt, J | 1 |
| Rabelink, TJ | 2 |
| Hoepelman, AI | 1 |
| Tomazic, J | 2 |
| Karner, P | 2 |
| Vidmar, L | 2 |
| Maticic, M | 2 |
| Sharma, PM | 1 |
| Janez, A | 2 |
| Koeppe, J | 1 |
| Kosmiski, L | 1 |
| Coll, B | 1 |
| Parra, S | 1 |
| Castro Cabezas, M | 1 |
| Hoepelman, IM | 1 |
| Ferre, N | 1 |
| Tous, M | 1 |
| Mulligan, K | 1 |
| Yang, Y | 1 |
| Wininger, DA | 1 |
| Parker, RA | 1 |
| Alston-Smith, BL | 1 |
| Schouten, JT | 1 |
| Fielding, RA | 1 |
| Basar, MT | 1 |
| Kohli, R | 1 |
| Shevitz, A | 1 |
| Gorbach, S | 1 |
| Wanke, C | 1 |
| Bradbury, RA | 1 |
| Samaras, K | 1 |
| Silic, A | 1 |
| Sharma, P | 1 |
| Nightingale, SL | 1 |
| Saint-Marc, T | 1 |
| Touraine, JL | 1 |
| Currier, JS | 1 |
| Corcoran, C | 1 |
| Basgoz, N | 1 |
| Davis, B | 1 |
| Sax, P | 1 |
| Meigs, JB | 1 |
| D'Agostino, RB | 1 |
| Wilson, PW | 1 |
| Lipinska, I | 1 |
| Tofler, GH | 1 |
| Grinspoon, SS | 1 |
| Kotler, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
| The Effect of Metformin on HIV Reservoir Size in Non-diabetic Antiretroviral Therapy (ART) Treated Participants: the Lilac Study[NCT02659306] | Phase 1 | 22 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
| Improving Treatment and Liver Fibrosis Outcomes With Metformin in HCV-HIV Co-infected and HCV Mono-infected Patients With Insulin Resistance.[NCT02306070] | Phase 2 | 0 participants (Actual) | Interventional | 2016-01-31 | Withdrawn (stopped due to insufficient funding) | ||
| Strategies for the Treatment of HIV Associated Metabolic Syndrome[NCT00399360] | 50 participants (Actual) | Interventional | 2006-12-31 | Completed | |||
| A Randomized, Double-Blind, Placebo-Controlled Study of Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Subjects With Hyperinsulinemia and Elevated Waist/Hip Ratio[NCT00015691] | 105 participants | Interventional | Completed | ||||
| Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382] | Phase 3 | 60 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly[NCT04841668] | 136 participants (Anticipated) | Observational | 2021-04-10 | Recruiting | |||
| [NCT00483392] | 0 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Abdominal visceral adipose area was assess by magnetic resonance imaging at the lvel of the L4 pedicle. The change in abdominal visceral adiposity between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | cm2 (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -22.6 |
| Lifestyle Modification and Placebo | -1.5 |
| No Lifestyle Modification and Metformin | -28.2 |
| Lifestyle Modification and Metformin | -35.0 |
High sensitivity C-reactive protein was determined by R&D Systems (Minneapolis, MN) kit. The change in C-reactive protein between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mg/l (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -0.27 |
| Lifestyle Modification and Placebo | -1.19 |
| No Lifestyle Modification and Metformin | 0.47 |
| Lifestyle Modification and Metformin | -1.92 |
A submaximal exercise stress test was conducted on a cycle ergometer to measure endurance. Subjects cycled between 50-60 revolutions per minute and the workload was progressively increased in increments of 50 watts in stages lasting 3 minutes. Once subjects became fatigued or reached their submaximal heart rate (220-age x 85), the test was stopped and separate readings of heart rate and blood pressure were measured at 1, 3, and 5 min of recovery. Weight-adjusted maximum oxygen consumption (VO2max; ml/kg per minute) was determined. The change in cardiorespiratory fitness between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | ml/kg/min (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -0.7 |
| Lifestyle Modification and Placebo | 2.0 |
| No Lifestyle Modification and Metformin | -1.3 |
| Lifestyle Modification and Metformin | 3.7 |
Carotid intima media thickness imaging of the common carotid artery was conducted using a high-resolution 7.5-MHz phased-array transducer (SONOS 2000/2500. The change of the carotid intima media thickness measurement between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mm (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -0.02 |
| Lifestyle Modification and Placebo | -0.02 |
| No Lifestyle Modification and Metformin | 0.00 |
| Lifestyle Modification and Metformin | 0.03 |
Computed tomography (CT) imaging was performed using a SOMATOM Sensation (Siemens Medical Solutions, Forcheim, Germany) 64-slice CT scanner. Agatston calcium score was calculated using CT images. The total Agatston score is calculated by summing up the scores of the individual calcifications in all slices of the CT scan. An absolute Agatston score of less than 10 indicates minimal overall atherosclerosis (plaques) in the coronary arteries. The change in the coronary artery calcium score between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | Agatston score (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | 43 |
| Lifestyle Modification and Placebo | 19 |
| No Lifestyle Modification and Metformin | 1 |
| Lifestyle Modification and Metformin | -4 |
Glucose level was determined after an overnight fast. The change in glucose between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -7 |
| Lifestyle Modification and Placebo | 3 |
| No Lifestyle Modification and Metformin | 2 |
| Lifestyle Modification and Metformin | -7 |
High density lipoprotein (HDL) was determined after an overnight fast. The change in HDL between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -2 |
| Lifestyle Modification and Placebo | 2 |
| No Lifestyle Modification and Metformin | 0 |
| Lifestyle Modification and Metformin | 4 |
Intramyocellular lipid (IMCL) of the tibialis anterior was determined using 1H-magnetic resonance spectroscopy (Siemens, Munich, Germany). The change in the intramyocellular lipid measurement between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mmol/kg (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | 0.6 |
| Lifestyle Modification and Placebo | -0.4 |
| No Lifestyle Modification and Metformin | 0.8 |
| Lifestyle Modification and Metformin | 0.1 |
Systolic blood pressure was measured after 5 minutes rest. The in systolic blood pressure between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mm Hg (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -5 |
| Lifestyle Modification and Placebo | -2 |
| No Lifestyle Modification and Metformin | -2 |
| Lifestyle Modification and Metformin | -6 |
Iliac waist circumference measurements were obtained using an inelastic tape measure. All measurements were obtained in triplicate, with the patient undressed, and then averaged. The change of the waist circumference measurement between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | cm (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -1.9 |
| Lifestyle Modification and Placebo | -0.1 |
| No Lifestyle Modification and Metformin | 0.3 |
| Lifestyle Modification and Metformin | -1.4 |
7 reviews available for metformin and HIV Coinfection
| Article | Year |
|---|---|
Metformin may be a viable adjunctive therapeutic option to potentially enhance immune reconstitution in HIV-positive immunological non-responders.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dysbiosis; | 2023 |
Metformin effect on gut microbiota: insights for HIV-related inflammation.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus; Disease Models, Animal; Dysbiosis; Gastrointes | 2020 |
The Bacterium
Topics: Akkermansia; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Dysbiosis; Gram-Negative Bacterial | 2020 |
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.
Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine | 2016 |
Metformin: new understandings, new uses.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I | 2003 |
Metformin: new understandings, new uses.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I | 2003 |
Metformin: new understandings, new uses.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I | 2003 |
Metformin: new understandings, new uses.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I | 2003 |
Therapeutic approaches to combating lipoatrophy: do they work?
Topics: Antiretroviral Therapy, Highly Active; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans | 2005 |
Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?
Topics: Antiretroviral Therapy, Highly Active; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, | 2008 |
19 trials available for metformin and HIV Coinfection
| Article | Year |
|---|---|
Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial.
Topics: Adolescent; Adult; Blood Glucose; COVID-19; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; | 2023 |
Effects of Brief Adjunctive Metformin Therapy in Virologically Suppressed HIV-Infected Adults on Polyfunctional HIV-Specific CD8 T Cell Responses to PD-L1 Blockade.
Topics: B7-H1 Antigen; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; HIV Infections; Humans; Male; Metfo | 2021 |
Effects of lifestyle modification and metformin on irisin and FGF21 among HIV-infected subjects with the metabolic syndrome.
Topics: Adipose Tissue, Brown; Adolescent; Adult; Aged; Body Composition; Body Mass Index; Female; Fibroblas | 2015 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome.
Topics: Adolescent; Adult; Aged; Atherosclerosis; Female; HIV Infections; Humans; Hypoglycemic Agents; Life | 2012 |
Side effects. Metformin for blood sugar problems.
Topics: Blood Glucose; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypogl | 2000 |
Encouraging Metformin data reported by researchers.
Topics: CD4 Lymphocyte Count; HIV Infections; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Vi | 2000 |
Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance.
Topics: Adipose Tissue; Adult; Biomarkers; Blood Glucose; Body Composition; Body Mass Index; Cardiovascular | 2002 |
Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
Topics: Adult; Antiretroviral Therapy, Highly Active; Body Constitution; Double-Blind Method; Female; Gemfib | 2003 |
Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients.
Topics: Adipose Tissue; Adult; Female; HIV Infections; Humans; Hypoglycemic Agents; Insulin; Male; Metformin | 2004 |
Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.
Topics: Adipose Tissue; Adolescent; Adult; Aged; Blood Glucose; Brachial Artery; Endothelium, Vascular; Fatt | 2005 |
Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol, HDL; Cholesterol, LDL; HIV Infections; Hu | 2005 |
Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; Aryldialkylphosphatase; Chemokine CCL2; Cholesterol, | 2006 |
Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
Topics: Adult; Body Composition; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infect | 2007 |
A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy.
Topics: Adipose Tissue; Adiposity; Adult; Area Under Curve; Female; HIV Infections; HIV-Associated Lipodystr | 2007 |
Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Blood Glucose; Drug Administration Schedul | 2007 |
Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Body Composition; Female; HIV Infections; HIV Protease Inhib | 1999 |
Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial.
Topics: Adult; Area Under Curve; Blood Glucose; Double-Blind Method; Female; HIV Infections; Humans; Hyperin | 2000 |
Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
Topics: Adipose Tissue; Adult; Cross-Sectional Studies; Female; HIV Infections; Humans; Hypoglycemic Agents; | 2001 |
24 other studies available for metformin and HIV Coinfection
| Article | Year |
|---|---|
Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide-1 Receptor; Glucag | 2022 |
Association Between Metformin Use and Cognitive and Physical Function in Persons with HIV and Diabetes.
Topics: Aged; Aged, 80 and over; Cognition; Cross-Sectional Studies; Diabetes Mellitus; Frailty; HIV Infecti | 2023 |
Elevated CD54 Expression Renders CD4+ T Cells Susceptible to Natural Killer Cell-Mediated Killing.
Topics: Adult; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cell Communication; Cytotoxicity, Immunolog | 2019 |
Trends in medication adherence in HIV patients in the US, 2001 to 2012: an observational cohort study.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-HIV Agents; | 2019 |
Lack of clinically relevant interactions between bictegravir and metformin in persons with diabetes and HIV.
Topics: Amides; Diabetes Mellitus; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; | 2021 |
Multi-omics analyses reveal that HIV-1 alters CD4
Topics: Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; Disease Models, Animal; Female; Gene Expressi | 2021 |
Evaluation of the concurrent use of dolutegravir and metformin in human immunodeficiency virus-infected patients.
Topics: Adult; Aged; CD4 Lymphocyte Count; Creatinine; Drug-Related Side Effects and Adverse Reactions; Fema | 2017 |
Dolutegravir and metformin: a case of hyperlactatemia.
Topics: Aged; Drug Interactions; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infe | 2017 |
Dolutegravir and metformin: a clinically relevant or just a pharmacokinetic interaction?
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Hyperlactatemia; Metformin; Oxazines; Pipera | 2018 |
Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol.
Topics: Adult; Anti-HIV Agents; Disease Reservoirs; Female; HIV Infections; HIV-1; Humans; Male; Metformin; | 2019 |
Metabolic stress in infected cells may represent a therapeutic target for human immunodeficiency virus infection.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Chloroquine; Genomic Instability; HIV Infections; HIV-1 | 2013 |
Cohort study of diabetes in HIV-infected adult patients: evaluating the effect of diabetes mellitus on immune reconstitution.
Topics: Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymphocyte Count; CD4-Positi | 2014 |
Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans.
Topics: Adult; Black or African American; Blood Glucose; Body Mass Index; Comparative Effectiveness Research | 2017 |
How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life?
Topics: Area Under Curve; CD4 Lymphocyte Count; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, | 2017 |
Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection.
Topics: Acidosis, Lactic; Acute Kidney Injury; Adenine; Aged; Anti-HIV Agents; Diabetes Mellitus, Type 2; Dr | 2011 |
Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.
Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Carbamates; Diabetes Mellitus, Type 2; Drug T | 2011 |
A case of lactic acidosis (LA) after administration of tenofovir and metformin in a diabetic patient with recently diagnosed HIV infection.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Diabetes Mellitus, Type 2; HIV Infections; Humans; Hypog | 2011 |
Metformin: a cheap and well-tolerated drug that provides benefits for viral infections.
Topics: Adult; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Coinfection; Cytomegalovirus; Cy | 2013 |
Body habitus changes related to lipodystrophy.
Topics: Androgens; Exercise; Growth Hormone; HIV Infections; Humans; Incidence; Lipodystrophy; Metformin; Pr | 2003 |
Summaries for patients. HIV lipodystrophy: rosiglitazone or metformin?
Topics: Adipose Tissue; Adolescent; Adult; Aged; Blood Glucose; Brachial Artery; Endothelium, Vascular; Fatt | 2005 |
Apparent resolution of type 2 diabetes mellitus after initiation of potent antiretroviral therapy in a man from Africa with HIV infection.
Topics: Antiretroviral Therapy, Highly Active; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glyburi | 2006 |
From the Food and Drug Administration.
Topics: Alcoholism; Diabetes Mellitus, Type 2; Drug Approval; Enzyme-Linked Immunosorbent Assay; HIV Antibod | 1995 |
How to manage metabolic complications of HIV therapy: what to do while we wait for answers.
Topics: Anabolic Agents; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Exercise Therapy; Gemfibro | 2000 |
Metabolic alterations in HIV lipodystrophy. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
Topics: Acidosis; Anti-HIV Agents; Bone Diseases, Metabolic; Cost-Benefit Analysis; Glucose; Glucose Intoler | 2001 |